What makes ExPatient Microtumors™ unique?
At Assay Engineers we are transforming preclinical cancer research with our ExPatient Microtumors™—a next-generation tumor model system that captures the full complexity of the human tumor microenvironment including their autologous immune competence.
Unlike PDX and expanded organoid systems, ExPatient Microtumors™ are non-cultured tumor biopsy preparations that preserve the native multicellular architecture. This includes the patient’s inherent immune environment, cellular heterogeneity, and critically, the autologous immune system—encompassing Tumor Infiltrating Lymphocytes (TILs) and Tumor Associated Macrophages (TAMs).
ExPatient Microtumors™ offer the most physiologically relevant model for immune-oncology research.
Key Benefits at a Glance:
- Maintains the full biological and immune composition of the original tumor.
- Ready-to-use within one week of biopsy—no engraftment, no synthetic modification.
- Applicable across all solid tumor types, including rare and aggressive forms.
- High translational relevance for patient-specific drug response.
ExPatient Microtumors™ enable powerful applications in:
- Checkpoint Inhibitor Testing – Assess T-cell activation and exhaustion in a native context.
- Immunomodulator Screening – Analyze effects on immune suppression and TAM behavior.
- Combination Therapy Development – Reveal synergistic interactions in a real tumor setting.
- Adoptive Cell Therapy Evaluation – Evaluate CAR-T and TCR therapies in an immune-intact tumor model.
ExPatient Microtumors™ preserve real patient tumor biology—fueling mechanism-of-action studies, biomarker validation, and immune-competent drug testing with exceptional relevance.
Whether you’re conducting in-house experiments or need support with deep multi-omics analysis (transcriptomics, proteomics, metabolomics, and more), Assay Engineers delivers the tools to accelerate your pipeline—with a sharp focus on patient specificity, functional accuracy, and non-alloreactivity.
#From the patient. For the patient.
